Cervical Cancer

The Food and Drug Administration approved the expanded use of the biomarker test CINtec PLUS Cytology that looks at HPV related biomarkers that could lead to cervical cancer. This is the first triage test approved in this space.

Make sure to prioritize your family health history to understand your risk of cancer.

Immunotherapy used after chemoradiotherapy shows better survival outcomes for patients with cervical cancer.

New biological advances are giving patients and their care teams a better understanding of cervical cancer — a disease that affects thousands each year.

Women who use copper intrauterine devices (IUD) as a form of birth control may be at lower risk for high-grade cervical cancer compared with those who use a levonorgestrel-releasing intrauterine system.

The World Health Organization has announced a vaccination-based initiative to eliminate cervical cancer as a public health problem in low to middle income countries.

For World Cancer Day, here are 6 hot topics making an impact in the cancer space.

Here is a list of clinical trials that are currently happening within the cervical cancer space.

Recent study findings showed that cervical cancer screening rates declined between ages 45 and 65, even as experts advise that women be screened through their lifetime.

A new study suggests distributing self-testing kits by mail helps bring effective testing to underserved populations and makes it easier for women to get tested on their own time.

Results from a new study suggest there may be a simpler, cheaper, more accessible way to screen for cervical pre-cancer.

Researchers from Yale Cancer Center have created a platform to identify genetic mutations that might drive cervical cancer.

Patients with recurrent, metastatic or persistent cervical cancer may benefit from the TIL immunotherapy LN-145.

Patients with recurrent or metastatic cervical cancer were treated with combination Opdivo and Yervoy in the CheckMate-358 clinical trial.

A essay nominating Kimberly Spina, B.S.N., RN for CURE®’s Extraordinary Healer® Award, written by Stephanie Fraser, M.S.W., of The University of Vermont Cancer Center.

Here are the top 5 CURE stories for January 2019.

Nearly 90 percent of women experienced sexual dysfunction; however, providers were not openly communicating about this side effect, according to survey results.

In conjunction with Cervical Cancer Awareness Month, recognized in the month of January, here are some fast facts about the disease.

The Food and Drug Administration (FDA) approved an expanded age indication for GARDASIL 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), according to Merck, the manufacturer of the HPV vaccine.

Non-pharmacologic integrative medicine approaches such as aromatherapy and reflexology can dramatically reduce the pain and anxiety associated with cervical radiation therapy, according to a clinical study currently underway at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

The application is seeking approval for GARDASIL 9 to be used in women and men aged 27 to 45 years for the prevention of certain cancers and diseases caused by the nine human papillomavirus (HPV) types covered by the vaccine.

The Food and Drug Administration approved Keytruda (pembrolizumab) for the treatment of certain patients with cervical cancer.

Keytruda (pembrolizumab) was granted a priority review by the Food and Drug Administration (FDA) for the treatment of patients with advanced cervical cancer with disease progression or after chemotherapy.

Treatment of HIV has drastically improved since the 1980s, but many of these individuals are still facing barriers to proper cancer care.

This HPV-based test can help identify women who are at an increased risk for cervical cancer.